Dr. Hugo Caicedo is a Sr. Director in the Accelerated R&D Leadership Program at Eli Lilly and Company.
I work on establishing robust formulations and manufacturing processes to support late-stage development of synthetic drug programs.
I support nonclinical safety studies for IND filing and clinical trials
I support the growth of the research division by maintaining effective pricing strategies such as contracts and negotiations to ensure a high level of customer satisfaction.
I manage laboratory teams and monitor the quality of their work, making sure reagents for projects are dispatched in a timely manner.
I lead and develop a team of field-based oncology Medical Science Liaisons where I provide guidance on medical insight
I utilize x-rays, MRIs, and 3D modeling programs while collaborating with surgeons to provide them with the desired results for their patients’ surgeries.
I lead research studies that use real-world data to support precision medicine strategy for the oncology products of the company.
I help with the research and development of next generation enabling technology and features for implantable neurostimulators.
As the 2022 Research and Development trainee for Merck’s KGaA, Darmstadt, Germany Rotational Program, I work with the In-Vitro Research and Development team to improve biosafety testing assays.
I oversee the continual improvement of medical devices as well as the design and manufacturing of new devices.
I oversee the overarching Diagnostics strategy for the Amivantamab program in biomarker-selected populations of Non-Small Cell Lung Cancer and other solid tumors.
I provide clinical and health economic information related to my company's Oncology portfolio.
I work on product development for medical devices, identifying user needs and transferring them into design inputs.
I help health insurance companies and hospital systems make decisions about providing access to the oncology therapies that we produce.